SF3B2-mediated RNA splicing drives human prostate cancer progression

Norihiko Kawamura, Keisuke Nimura, Kotaro Saga, Airi Ishibashi, Koji Kitamura, Hiromichi Nagano, Yusuke Yoshikawa, Kyoso Ishida, Norio Nonomura, Mitsuhiro Arisawa, Jun Luo, Yasufumi Kaneda

Research output: Contribution to journalArticlepeer-review

Abstract

Androgen receptor splice variant-7 (AR-V7) is a constitutively active AR variant implicated in castration-resistant prostate cancers. Here, we show that the RNA splicing factor SF3B2, identified by in silico and CRISPR/Cas9 analyses, is a critical determinant of AR-V7 expression and is correlated with aggressive cancer phenotypes. Transcriptome and PAR-CLIP analyses revealed that SF3B2 controls the splicing of target genes, including AR, to drive aggressive phenotypes. SF3B2-mediated aggressive phenotypes in vivo were reversed by AR-V7 knockout. Pladienolide B, an inhibitor of a splicing modulator of the SF3b complex, suppressed the growth of tumors addicted to high SF3B2 expression. These findings support the idea that alteration of the splicing pattern by high SF3B2 expression is one mechanism underlying prostate cancer progression and therapeutic resistance. This study also provides evidence supporting SF3B2 as a candidate therapeutic target for treating patients with cancer.

Original languageEnglish (US)
Pages (from-to)5204-5217
Number of pages14
JournalCancer Research
Volume79
Issue number20
DOIs
StatePublished - Oct 15 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'SF3B2-mediated RNA splicing drives human prostate cancer progression'. Together they form a unique fingerprint.

Cite this